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Abstract
Background: Little is known about the immunopathogenesis of Chikungunya virus. Circulating levels of immune mediators
and growth factors were analyzed from patients infected during the first Singaporean Chikungunya fever outbreak in early
2008 to establish biomarkers associated with infection and/or disease severity.
Methods and Findings: Adult patients with laboratory-confirmed Chikungunya fever infection, who were referred to the
Communicable Disease Centre/Tan Tock Seng Hospital during the period from January to February 2008, were included in
this retrospective study. Plasma fractions were analyzed using a multiplex-microbead immunoassay. Among the patients,
the most common clinical features were fever (100%), arthralgia (90%), rash (50%) and conjunctivitis (40%). Profiles of 30
cytokines, chemokines, and growth factors were able to discriminate the clinical forms of Chikungunya from healthy
controls, with patients classified as non-severe and severe disease. Levels of 8 plasma cytokines and 4 growth factors were
significantly elevated. Statistical analysis showed that an increase in IL-1b, IL-6 and a decrease in RANTES were associated
with disease severity.
Conclusions: This is the first comprehensive report on the production of cytokines, chemokines, and growth factors during
acute Chikungunya virus infection. Using these biomarkers, we were able to distinguish between mild disease and more severe
forms of Chikungunya fever, thus enabling the identification of patients with poor prognosis and monitoring of the disease.
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Introduction
In the recent years, emerging and re-emerging tropical
infectious diseases have been shown to cause high social and
economic impact. Vector-borne infectious diseases such as
Dengue, West Nile have been resurging largely due to the spread
of insecticide resistance, to socio-demographic changes, and to
genetic mutations in the pathogens. More recently, chikungungya
fever (CHIKF) has now emerged as the next important infection in
South-East Asia, the Pacific region and Europe [1–5], making it a
major threat that requires immediate attention. Recent epidemic
resurgence of CHIKF in several African and Asian countries
demonstrated that infection can spread alarmingly rapidly [6–9]
from limited early transmission that then developed into an
unprecedented and unexpected epidemic, infecting 38% of the
population as occurred in Reunion island [6,8]. The appearance
of cases in Europe, the United States and other countries by
travelers returning from known outbreak areas underscores the
contributory factors of increased human mobility, tourism, global
climate change, and increases in insecticide resistance [10–15]. In
this era of globalization, the threat of such disease epidemics
should not be underestimated as such public health events could
cripple public health systems and economies.
Chikungunya virus (CHIKV), which causes CHIKF, is an
alphavirus of the Togaviridae family, with a 12,000-nucleotides
linear, positive-sense, single-stranded RNA genome containing
two large open reading frames (ORF). The first, ORF1, encodes 4
non-structural proteins (nsP1, nsP2, nsP3 and nsP4) while ORF2
encodes structural proteins that include 1 capsid protein (C), 2
major envelope surface glycoproteins (E1, E2) and 2 small proteins
(E3, 6K) [8,9]. CHIKV is transmitted by Aedes mosquitoes (mainly
A. albopictus and A. aegypti).
CHIKF is an acute illness with abrupt fever, skin rash,
arthralgia, and occasional involvement of the nervous system,
heart and liver. Prolonged incapacitating arthralgia has sometimes
been reported to persist for years [8,9,13]. It is of concern that the
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fatalities, whereas previously CHIKF was considered as relatively
benign. Despite the fact that the clinical features of recent acute
CHIKV infections from several countries have been described
[16–18], little is known about the long-term sequelae or the
pathogenesis of arthropathy, and the acquisition of protective
immunity remains unexplored. It has been proposed that CHIKV-
induced arthritis or arthralgia is of immunopathologic origin
[19,20]. At present, there is no specific or effective treatment for
CHIKF, and patient management is largely symptomatic relief
and primarily anti-inflammatory drugs [8]. Given the expanding
geographic range of CHIKV and its potential to rapidly cause
large scale epidemics, it has become important to understand the
immune and pathogenic mechanisms active during CHIKV
infections in order to guide the development of targeted and
effective control and treatment strategies.
Cytokines and chemokines are thought to play an important
role in viral immunopathology. Although IL-2. IL-10 and IFN-c
have been implicated in the pathogenesis of CHIKF [21], a global
analysis of their specific involvement with disease severity has not
yet been defined. Growth factors are usually produced in response
to injury. Viral infections such as CHIKV, induce cellular damage
which may lead to secretion of these factors; however, limited
studies have been conducted [21]. In this study, we took the
opportunity to conduct a detailed study on the patients from the
first outbreak of CHIKF in Singapore [22,23]. We measured
circulating levels of a wide range of cytokines, chemokines, and
growth factors in 10 laboratory confirmed cases of CHIKF, and
compared them with healthy individuals. We next determined
which biomarker was associated with infection and/or severity.
We showed for the first time that CHIKV infection induced a wide
range of cytokines, chemokines, and growth factors. We
subsequently found that 3 specific biomarkers, namely IL-1b,
IL-6, and RANTES levels, were associated with severe CHIKF.
Results
All 10 patients included in this study were males. Their age
ranged from 22 to 65 years (median, 35 years). All except one were
foreign nationals. Half of our patients were classified as severe
CHIKF. We defined severe CHIKF as having a temperature of
.38.5uC or pulse rate .100/min, or platelet count ,100610
9 g/
L based on studies defining severe diseases [24–28]. Except for the
Singapore resident, none had any pre-existing medical condition.
Despite being previously healthy, four non-residents developed
severe illness. Fever lasted 2–10 days, and fever duration was not
significantly different between those who had more severe illness
and those who had not (mean, 6.6 days vs. mean, 3.8 days;
P.0.05). Two patients reported persistent arthralgia lasting more
than two weeks. Demographic and clinical details of the 10
CHIKF patients are summarized in Table 1.
Among our patients, the most common clinical features were
fever (100%), arthralgia (90%), rash (50%), and conjunctivitis
(40%) (Table 2). Gastrointestinal and constitutional symptoms
were less prominent. Arthritis was observed in only one patient,
who had an effusion on the right knee. None had neurologic
involvement or hemorrhagic manifestation.
Table 3 presents a summary of the key laboratory findings
among our patients throughout the course of their illness. White
cell count, hemoglobin, hematocrit, platelet count, erythrocyte
sedimentation rate for most patients were within the normal range.
The mean nadir platelet count (6SD) was 1996115610
9/L. Only
one patient had severe thrombocytopenia (nadir platelet count,
Table 1. Demographic and epidemiologic data on 10 patients with PCR-confirmed chikungunya infection.
Patient No. Age (years) Gender Nationality
Duration of
fever (days) Illness severity
a Pre-morbid condition Clinical Outcome
b
1 45 M Bangladeshi 2 Not Severe None Persistent arthralgia
2 32 M Bangladeshi 4 Not Severe None Complete recovery
3 33 M Indian 5 Not Severe None Complete recovery
4 45 M Indian 5 Not Severe None Complete recovery
5 28 M Malaysian 3 Not Severe None Complete recovery
6 65 M Singapore resident 10 Severe Liver cirrhosis, hypertension,
atrial fibrillation, anaemia
Complete recovery
7 34 M Indian 4 Severe None Complete recovery
8 39 M Indian 6 Severe None Persistent arthralgia
9 37 M Indian 9 Severe None Complete recovery
10 22 M Malaysian 4 Severe None Developed myalgia
aSeverity was defined as having a temperature .38.5uC or pulse rate .100/min or platelet count ,100610^9/L.
bClinical outcome at 2 weeks post-illness onset.
doi:10.1371/journal.pone.0004261.t001
Table 2. Clinical features.
Sign/Symptom No. (%) of patients
Fever 10 (100)
Arthralgia 9 (90)
Rash 5 (50)
Conjunctivitis 4 (40)
Gastrointestinal symptom
a 3( 3 0 )
Headache 3 (30)
Eye pain 2 (20)
Back pain 2 (20)
Mylagia 1 (10)
Arthritis 1 (10)
aNausea, vomiting, diarrhoea, or abdominal pain.
doi:10.1371/journal.pone.0004261.t002
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9/L) during the course of his illness. Elevated C-reactive
protein levels (CRP, .10.0 mg/L) were observed in 60% of
patients, but the peak C-reactive protein level was not significantly
different between those who classified as severely ill and those who
were not (mean, 40.3 mg/L vs. mean, 9.9 mg/L; P=0.195). The
mean peak alanine and aspartate transaminases (ALT and AST)
(6SD) were 58636 U/L and 50625 U/L respectively. Both ALT
and AST were 2-fold greater than the upper limit of normal in one
patient, who had pre-existing liver cirrhosis. None of the patients
had a clinically abnormal total protein, urea or creatinine level.
Among our patients, the mean nadir protein level (6SD) was
6765 g/dL, and the mean peak urea and creatinine levels (6SD)
were 5.161.7 mmol/L and 101616 mmol/L respectively. Lac-
tate dehydrogenase level was the only laboratory parameter that
was significantly higher in severely ill patients, compared to those
who were not (mean, 732 U/L vs. mean, 525 U/L; P=0.047).
Profiles of 30 cytokines, chemokines and growth factors were
determined by a multiplex-microbead immunoassay on acute blood
samples collected upon hospitalization. The samples collected
ranged from day 2 to day 19 of illness (median, day 4.5). To
characterize the overall patterns, a two-way hierarchical clustering
analysis was done to allow the classification of individuals according
to disease severity based on the clinical features (Figure 1).
Evidently, this had the power to discriminate the clinical forms of
CHIKF in the samples in this study from the healthy controls, with
patients classified as non-severe and severe disease segregating
perfectly. The levels of 8 plasma cytokines (IL-2R, IL-5, IL-6, IL-7,
IL-8, IL-10, IL-15 and IFN-a) were observed to be most
significantly elevated (Figure 2a) in CHIKF patients compared to
uninfected subjects (P,0.05). Among these was proinflammatory
cytokine, IL-6 which was very significant. Interestingly, another
proinflammatory cytokine, IL-8 was down-regulated in these
patients. Anti-inflammatory cytokine, IL-10 was found to be
significantly raised in most of the patients (P,0.05). The plasma
concentrations of IL-2R and IL-5 were found to be increased in all
patients. Levels of IFNa and IL-7 were elevated in all patients. The
levels of other cytokines such as IL-2, IL-4, IL-12, IL-13, IL-17,
IFN-c, and TNF-a, were only marginally increased in the CHIKF
group compared with those in the uninfected group (Figure S1).
Profiles of chemokines, IP-10 and MIG were shown to be
significantly elevated, while Eotaxin was suppressed (Figure 2b).
There was no difference in the levels of other chemokines namely,
MCP-1, MIP-1a, MIP-1b and RANTES (Figure S1).
Interestingly, the levels of 4 growth factors were found to be
significant in the patients, with up-regulation of HGF, FGF-basic
and VEGF, with the exception of EGF which was almost totally
suppressed (Figure 2c). It was observed that the CHIKF patients
exhibited low levels of GM-CSF and G-CSF (Figure S1).
Finally, in an effort to identify cytokine, chemokine, and growth
factor plasmatic levels associated with severity, statistical analyses
were performed after stratification of the CHIKF patients
according to severity. It was observed that an increase in levels
of IL-1b and IL-6, and a decrease in RANTES respectively were
associated with disease severity (Figure 3a). The levels of all other
markers were not significantly different (Figure S2 and S3).
Discussion
CHIKF, an emerging arboviral infection, which induces high
fever, has only been recently reported in Singapore. Up to Dec 2007,
all CHIKF patients had contracted the infection overseas [22]. The
first local outbreak of CHIKF occurred in Jan 2008. More than 2,500
people who lived or worked in the outbreak area were screened and a
total of 13 PCR-confirmed cases were identified [22,24]. All
confirmed CHIKF cases were referred to the CDC/TTSH. Our
report included 10 patients who participated in this study.
Phylogenetic analysis of the viral sequences of our patients has
revealed that the circulating strains were of the Indian Ocean
genotype and closely related to those from the 2006 outbreak in
India [29] but without the A226V mutation, further emphasizing
how remarkably rapid the disease could spread with the right
environmental conditions. The attack rate in our outbreak was
0.5%, much lower than the 34% reported in Reunion Island and
the 5.4% observed in Italy [13,30]. This could be attributed to the
rapid removal of human reservoirs through isolation, enhanced
vector control, or the circulation of a virus strain of lower epidemic
potential. Clinical features of our patients were similar to those
reported in recent outbreaks [6–9,11–14,16–18,21,30], indicating
that although people are genetically diverse response to diseases is
homogeneous across people in non-homogeneous populations.
The majority of our patients was #45 years and had no pre-
morbid condition. Unlike patients reported in the Reunion Island
outbreak [6], where the patients’ underlying medical conditions
could have contributed to the observed morbidities, our patients
were younger and healthier. Furthermore, none of our patients
was co-infected with dengue, as confirmed by RT-PCR and
dengue enzyme-linked immunoabsorbent assay (ELISA)-IgM and
IgG [31]. Hence, our immunologic observations can be largely
attributed to acute CHIKV infection itself.
In recent years, most of the studies on CHIKF have been
addressed with the clinical description of the disease [4–
9,11,17,18,21], the molecular nature of the virus [9,10,19] and
diagnosticsmethods[8–10,24],andtheinteractionsofthe viruswith
its mosquito vector, Aedes [1–3,11–15]. Here, we describe for the
first time the comprehensive systemic production of cytokines,
chemokines, and growth factors during acute CHIKV infection
which may light the path ahead in understanding the innate
response to the infection. We first showed that a wide range of
cytokines such as IFN-a, IL-5, IL-6, IL-7, IL-10, IL-15 were
produced in response to CHIKV infection. IFN-a is a potent anti-
viral cytokine and has been shown to strongly inhibit CHIKVin vitro
[32]. The high levels of IFN-a that we detected provide a logical
explanation for how the body rapidly brings CHIKV viremia under
control [8,11]. It has been shown that the main producers of IFN-a
are plasmocytoid dendritic cells [33] and monocytes [34].
Table 3. Laboratory parameters in chikungunya confirmed
patients.
Variable Normal range Mean6SD
Nadir white cell count, 610^9/L 3.6–9.3 4.561.1
Nadir hemoglobin, g/dL 13.0–17.0 14.661.3
Peak hematocrit, % 41.0–51.0 46.663.4
Nadir platelet count, 610^9/L 170–420 1996115
Peak erythrocyte sedimentation rate (ESR), mm/hr 1–10 768
Peak C-reactive protein (CRP), mg/L 0.0–5.0 26.8633.7
Peak alanine transaminase (ALT), U/L 17–63 58636
Peak aspartate transaminase (AST), U/L 15–41 50625
Nadir total protein, g/dL 63–81 6765
Peak urea, mmol/L 2.9–9.3 5.161.7
Peak creatinine, umol/L 60–110 101616
Peak lactate dehydrogenase (LDH), U/L 250–580 654650
doi:10.1371/journal.pone.0004261.t003
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Type 2 cytokines. Mainly IL-5, IL-6 and IL-10 levels were increased
and those of IFN-c or TNF-a were unchanged as compared to non-
infected controls. This suggests that acute CHIKV infection tilts the
cytokine profile to anti-inflammatory response, which would argue
against the common understanding of CHIKV infection which does
not really support the common description of the CHIKV infection
as an inflammatory disease [8]. Alternatively, it is possible that an
inflammatory response might occur earlier when the virus is actively
replicating, and then gets down-regulated by a counter-anti-
inflammatory response when the virus is being eliminated from
circulation. High levels of anti-inflammatory IL-10 and the presence
of high levels of chemokines IP-10 and MIG (ligands of CXCR3
associated with Th1-type reactions) [35], detected here would
support this hypothesis. Further studies would be needed to clarify
this issue. The Type 2 cytokines detected are also important
mediators of B cell growth and maturation, and thus may allow the
production of high levels of persisting anti-CHIKV IgG [5].
The detection of high levels of circulating IL-15 is of interest,
since this cytokine has been shown to be a major stimulator of NK
Figure 1. Two-way hierarchical clustering analysis. Each cell in the 2-dimensional graph indicates the measure of a single mediator in 1 sample,
with standardized levels indicated by color according to the scale on the top. Sample clustering resulting from the algorithm described is shown at
the right side of the graph, with an indication of the group to which each individual sample belongs. Mediator clustering is depicted on the top of the
graph, and detailed at the bottom.
doi:10.1371/journal.pone.0004261.g001
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lymphocytes population might be activated during acute infection
and may also contribute to viral control during the acute phase of
CHIKV infection. Detection of soluble IL-2R in the plasma suggests
T cell activation since this molecule is secreted by activated T cells
[38]. Experiments are planned to study the activation phenotype of
T and NK cell subsets in acutely infected patients.
The detection of IL-7 and IL-15 is significantly interesting with
regardsto theimmunopathology ofCHIKF sinceCHIKV infection
has been shown to induce rapidly developing and persisting
arthralgia [6]. Here, 9 of the 10 patients manifested this pathology.
IL-7 is known to have an important role in the development of
rheumatoid arthritis [39], while IL-15 has been associated with the
development of joint inflammation [40]. It has been proposed that
expansion of a particular IL15-induced NK cell subsets was
responsible for this phenomenon [41]. The role of IL-15 and NK
cells in the development of CHIKV arthralgia would definitively be
worth investigating. We did not detect TNF-a in the plasma of the
patients with acute CHIKV infection. This is surprising since this
cytokine has been detected repeatedly in the blood of patients
suffering from other arthritides such as rheumatoid arthritis and is
known to be involved in the pathogenesis of these entities [42].
Thus,itispossible thatCHIKV-inducedarthralgiadoesnotdepend
on TNF-a. Alternatively, TNF-a might be produced only locally.
Analysis of synovial fluid or joint tissue immunohistochemistry
would be necessary to provide important information on the role of
TNF-a and other mediators.
Chemokines are crucial mediators of innate and adaptive
immunity against various viral infections [43]. IP-10, and MIG
had increased plasma levels during CHIKV infection. These two
chemokines signal through the same receptor CXCR3 and thus
might activate and direct migration of this T cell subset [35]. IL-8
and Eotaxin levels were lower than those of naive controls.
Defining the exact contributions of these different chemokines will
require further studies.
We also tested the presence of growth factors in the plasma of
CHIKV-infected patients. HGF, FGF-basic and VEGF were
produced at high levels and may reflect a physiological response to
tissue destruction resulting for the viral infection. Interestingly, EGF
levels were lower than in healthy controls. The low levels of EGF
might be due to the concomitant decrease of platelets observed in
infected patientssince previous studieshave shown thatplasmalevels
of EGF are associated with circulating platelets [44].
Although limited, we had access to sufficient patients to perform
data analysis in relation to the severity of the disease (severe illness
was defined as fever .38.5uC, or maximum pulse rate .100
beats/minute, or nadir platelet count ,100610
9/L). Using this
definition, we observed that higher disease severity was associated
with increased plasma levels of IL-1b and IL-6 and a decreased
level in RANTES (Figure 3b). IL-1b and IL-6, whose levels are
already high in the CHIKV infected patients, are potent
endogenous pyrogens [45–48]. Therefore, elevations of IL-1b
and IL-6 might account for the high fever in the severe cases. The
increase production of IL-1b might also mediate the development
Figure 2. Differences in plasma mediator levels in CHIKF patients and healthy controls. a. Levels of cytokines (pg/ml) were determined as
described and only those with a P value of ,0.05 are illustrated. Horizontal bars indicate the respective groupwise medians. b. Levels of chemokines
(pg/ml) were determined. c. Levels of growth factors (pg/ml) were determined.
doi:10.1371/journal.pone.0004261.g002
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the immunopathogenesis of many arthritic pathologies such as
rheumatoid arthritis [49]. On the contrary, T cell chemokine
RANTES levels were significantly suppressed in severe CHIKF
patients. Platelets are a major reservoir of RANTES in the
peripheral circulation [50], and severe CHIKF was characterized
by thrombocytopenia. Thus, as mentioned above for EGF,
thrombocytopenia can also reduce levels of circulating RANTES.
Low levels of RANTES correlate with disease severity and mortality
in individuals with severe malaria, who were also correspondingly
thrombocytopenic [51]. Interestingly, it was observed in other
studies that RANTES levels were up-regulated in dengue [48],
except for one single report from Cuba [52]. Since the symptoms of
CHIKF mimic those of dengue fever, results obtained from this
study strongly suggest that RANTES could be a potential biomarker
that differentiates between these 2 clinically very similar diseases.
One limitation of this study is in the classification of disease
severity as none of our patients developed neurologic or
hemorrhagic complications previously reported in CHIKF
patients. Nonetheless, our definition of severe illness would have
included patients with sepsis, a serious form of infection commonly
associated with a temperature of .38uC and heart rate of .90/
minute [24]. Furthermore, we included thrombocytopenia of
,100610
9/L as a criteria for severe CHIKF. Marked thrombo-
cytopenia is a common feature of sepsis [25] and has been
identified as a predictor of mortality [26,27]. The degree of
thrombocytopenia is a determinant of survival and once the
platelet count decreases below 100610
9/L, mortality continues to
increase, even though the risk of bleeding does not [28]. A wide
spectrum of disease has been reported in CHIKF ranging from
asymptomatic infections, to self-limiting febrile illness [8], to
neurologic complications, and death [17]. The ‘‘severe illness’’
cohort in our study possibly represents a more severe form of self-
limiting febrile illness, an intermediate group with higher levels of
viremia (data not shown) and distinctly more severe clinical
features (i.e. high temperature, tachycardia, and severe thrombo-
cytopenia). Using this clinical phenotype, we have shown in this
study that immune mediators are able to distinguish very mild
disease from more severe forms of CHIKF disease at the acute
stage. Follow-up studies will be required to determine if long-term
sequelae are indeed different between non-severe and severe
clinical presentations. Elucidating the association of disease
severity with two cytokines and one chemokine can be useful in
order to provide early identification and monitoring of patients
with severe disease. Although this study is limited by the size of the
outbreak, nevertheless, based on these observations, measurement
of immune mediators could be helpful for the management of
future outbreaks. This study strongly suggests these biomarkers be
used for measuring disease severity and be tested in outbreaks in
different populations and different strains. Once confirmed, they
will be useful for follow-up studies, association studies, and
prognosis for public health management. More importantly, these
biomarkers can potentially lead to the development of modulators
to reduce disease severity and to halt disease progression.
Figure 3. Differences in cytokines, chemokines and growth factors levels determine disease severity. a. Box-and-whisker plots
illustrating the significant differences of IL-1b, IL-6 and RANTES in patients with non-severe and severe CHIKF. b. Diagrammatic representation of the
mediator profiles in CHIKV-infected patients and healthy control subjects, and the distinction between non-severe and severe CHIKF.
doi:10.1371/journal.pone.0004261.g003
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Patients and Clinical Samples
Ten patients who presented with acute CHIKF to the
Communicable Disease Centre at Tan Tock Seng Hospital
(CDC/TTSH), the national infectious disease referral centre in
Singapore, during the outbreak period from January to February
2008, were included in this study. An acute case of CHIKF was
defined as any case with clinical features consistent with CHIKF,
and hadCHIKVinfectionconfirmedbyeitherreversetranscription-
polymerase chain reaction (RT-PCR) or virus isolation [53,54]. The
study was approved by the institution’s domain-specific ethics review
board (DSRB Reference No. B/08/026). Written consent was
obtained from each patient and healthy control subject.
Plasma samples were obtained from patients during the acute
phase of their illness. Data on demographic characteristics, pre-
morbid conditions, clinical features, and routine hematological and
biochemical laboratory test findings (i.e. full blood count, renal and
liver function tests, C-reactive protein) were also collected. All
symptomatic patients were isolated at CDC/TTSH until the febrile
illness resolved and a negative CHIKV RT-PCR test was obtained.
During the hospital stay, daily monitoring of body temperature, vital
parameters, and blood counts were carried out. A patient was
defined as having severe illness, if he had either a maximum
temperature of more than 38.5uC, or a maximum pulse rate of more
than 100 beats/minute, or a nadir platelet count of less than
100610
9/L. Laboratory results were expressed as mean6SD.
In addition, plasma or serum samples from 9 healthy volunteers
(who did not have a febrile illness in the preceding week and were
not epidemiologically-linked to the outbreak) were also included as
controls in our study.
Multiplex Microbead Immunoassay
Plasma samples collected as described above, were aliquoted and
stored at 280uC until analyses were done. A multiplex biometric
immunoassay, containing fluorescent dyed microspheres conjugat-
edwithamonoclonalantibodyspecificforatargetprotein,wasused
for cytokine measurement according to manufacturer’s instructions
(Biosource Human Cytokine 30-plex Assay, Invitrogen). The
following groups of cytokines were: inflammatory (GM-CSF, IL-
1beta, IL-1RA, IL-6, IL-8, TNF-alpha); Th1/Th2 (IFN-gamma,
IL-2, IL-2R, IL-4, IL-5, IL-10); Cytokine II (IFN-alpha, IL-7, IL-
12p40/p70, IL-13, IL-15, IL-17); Chemokines (Eotaxin, IP-10,
MCP-1, MIG, MIP-1alpha, MIP-1beta, RANTES); and Growth
Factors (EGF, HGF, FGF-basic, G-CSF, VEGF). Briefly, 25 ul of
plasma samples were diluted in 1:2 and incubated with antibody
coupledbeadsfor2 h atRTuC.Complexeswerewashedtwicewith
the use of a vacuum manifold before incubation with biotinylated
detector antibody for 1 h at RT uC. Complexes were then washed
twice followed by incubation with Streptavidin-phycoeryrhrin
(RPE) for 30 min at RT uC. Complexes were washed thrice and
incubated with wash buffer for another 3 min before detection in
theLuminex200
TMinstrument.ResultswereacquiredbytheIS2.3
software and the standard curves were plotted through a five-
parameter logistic curve setting.
Algorithms for Data Analyses
To compare and analyze the expression profiles across the
results, the raw cytokine values were normalized using z-score
conversion based on the formula:
z~
x{m
s
where x is the raw value to be converted, m is the mean of the
population and s is the standard deviation (SD) of the population.
The transformed value is denoted by z and exhibits positive value
when the raw value is above mean and vice versa. Further, to
examine the nuances and correlations masked in the full set of data,
the z values are subjected to cluster analysis [55] to yield an ordered
NumOfRows.x NumOfCols expression level matrix, Eel. Hierarchi-
cal clustering is applied on the columns which represent the myriad
of cytokine levels measurements (e.g.) based on McQuitty’s or
WPGMA method [56] where the distance between a pair of groups
A and B is measured using the weighted arithmetic mean of all the
pairwise distances between the data points in A and B. The rows
which represent the suspected CHIKF patients and healthy
individuals are left untouched. Seriation [57] is performed following
the clustering approach to re-order the clustered data points using
the minimum path length algorithm to minimize the sum of all the
distances between adjacent columns.
S~
X n{1
i~1
di ,iz1 ðÞ
Euclidean distance is used in both the clustering and seriation phases
to measure the difference or dissimilarity, d, between data points (x1,
y1) and (x2,y 2) given by the equation:
d~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
x2{x1 ðÞ
2z y2{y1 ðÞ
2
q
Statistical Analyses
Comparisons between groups were calculated by Mann-
Whitney rank sum. Further statistical analyses were done by
Kruskal-Wallis test followed by Dunn’s multiple comparison tests.
P values of ,0.05 were considered to be statistically significant.
Supporting Information
Figure S1 Complete profile of the levels (pg/ml) of cytokines,
chemokines and growth factors determined by multiplex-bead
arrays from blood samples collected from CHIKV-infected
patients and healthy control subjects.
Found at: doi:10.1371/journal.pone.0004261.s001 (0.33 MB EPS)
Figure S2 Box-and-whisker graphs of 14 immune mediators
(cytokines and chemokines) determined from blood samples collected
from healthy control subjects and CHIKV-infected patients.
Found at: doi:10.1371/journal.pone.0004261.s002 (0.40 MB EPS)
Figure S3 Box-and-whisker graphs of 13 Chemokines and
growth factors determined from blood samples collected from
healthy control subjects and CHIKV-infected patients.
Found at: doi:10.1371/journal.pone.0004261.s003 (0.40 MB EPS)
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